<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033471</url>
  </required_header>
  <id_info>
    <org_study_id>464</org_study_id>
    <nct_id>NCT04033471</nct_id>
  </id_info>
  <brief_title>Combined Epidural Morphine and Midazolam on Postoperative Pain</brief_title>
  <official_title>Effect of Epidural Morphine and Midazolam on Postoperative Painin Patients Undergoing Major Abdominal Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study aim to Compare the effect of preoperative Epidural Midazolam, Morphine and their
      combination in postoperative pain relief and total morphine consumption by P.C.A device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major abdominal surgeries with abdominal incisions lead to severe abdominal pain, which if
      treated inadequately, can cause shallow breathing, atelectasis, retention of secretions and
      lack of cooperation in physiotherapy. This increases the incidence of post-operative
      morbidity and leads to delayed recovery.Epidural anesthesia is safe and inexpensive technique
      with the advantage of providing surgical anesthesia and prolonged postoperative pain relief.
      It also an effective treatment of operative pain blunts autonomic, somatic and endocrine
      responses. Morphine and midazolam can be used as adjuvant to bupivicain to reduced the
      postoperative pain
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>epidural bupiviacain</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to first request of IV-PCA morphine for analgesia</measure>
    <time_frame>1st 48 hours postoperative</time_frame>
    <description>the time between the end of operation and tracheal extubation to the first request for supplemental analgesics and its administration to the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>and the cumulative consumption of morphine PCA in the 1st 48h postoperatively</measure>
    <time_frame>1st 48 hours postoperative</time_frame>
    <description>total amount of IV morphine used for analgesia</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>BM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.25% + midazolam 10mg in total volume 10m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.25% + midazolam 10mg and morphine 5mg in total volume 10ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bupivacaine 0.25% in total volume 10 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>BM</arm_group_label>
    <arm_group_label>BMM</arm_group_label>
    <other_name>morphine</other_name>
    <other_name>bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II patients scheduled for major abdominal cancer surgeries

        Exclusion Criteria:

          -  patients with known allergy to the study drugs,

          -  significant cardiac, respiratory, renal or hepatic disease,

          -  drug or alcohol abuse,

          -  psychiatric illness that would interfere with perception and assessment of pain.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shereen M Kamal, Associate proferssor</last_name>
    <phone>01006279209</phone>
    <email>sheridouh79@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khaled M Fares, proferssor</last_name>
    <phone>01289757288</phone>
    <email>faressali@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shereen M Kamal, Degree</last_name>
      <phone>01006279209</phone>
      <email>sheridouh79@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Khaled M Fares, Professor</last_name>
      <phone>01289757288</phone>
      <email>faressali@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shereen Mamdouh</investigator_full_name>
    <investigator_title>associate professor of anesthesia, ICU and pain manegement</investigator_title>
  </responsible_party>
  <keyword>epidural, morphine, midazolam, acute postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

